ENDRA Life Sciences Reports 2025 Financial Results and Highlights Strategic Progress
ENDRA Life Sciences Inc a company focused on advancing thermoacoustic biomarker imaging technology, has announced its financial results for the fourth quarter and full year ended December 31, 2025. Alongside its financial performance, the company also shared key business developments, including clinical progress, operational improvements, and strategic initiatives aimed at enhancing long-term shareholder value.
The company continues to position itself as an innovator in the early detection and monitoring of steatotic liver disease (SLD), a condition that affects a significant portion of the global population.
Strategic Review Process Underway
One of the most notable updates from ENDRA is the initiation of a strategic review process. On March 25, 2026, the company’s Board of Directors announced that it had begun evaluating a range of strategic alternatives. The primary objective of this initiative is to identify opportunities that could maximize shareholder value.
While the company has not disclosed specific options under consideration, such reviews typically include potential partnerships, mergers, acquisitions, or other corporate restructuring strategies. Importantly, ENDRA emphasized that it will continue executing its current business and operational plans throughout this evaluation period.
The company also noted that there is no fixed timeline for completing the review, indicating a thoughtful and deliberate approach to identifying the best possible outcome for stakeholders.
Significant Clinical Progress with TAEUS Liver Technology
ENDRA highlighted substantial advancements in the development and validation of its flagship technology, TAEUS® Liver, over the past year. This system is designed to provide a non-invasive, accessible, and cost-effective method for assessing liver fat, a critical biomarker in SLD.
Strong Feasibility Study Results
On November 20, 2025, the company reported positive results from a feasibility study evaluating the redesigned TAEUS Liver system. The study demonstrated the device’s ability to accurately measure liver fat fraction, achieving a Pearson correlation coefficient of 0.89 across a wide range of disease stages and body mass index (BMI) levels.
This level of correlation indicates a strong agreement between TAEUS measurements and established benchmarks, reinforcing the technology’s potential as a reliable diagnostic tool.
Alignment with Industry Gold Standard
Further strengthening its clinical credibility, ENDRA announced additional findings on December 4, 2025. These results showed that TAEUS Liver exhibits strong concordance with MRI-PDFF (magnetic resonance imaging-proton density fat fraction), which is widely regarded as the gold standard for non-invasive liver fat quantification.
The device performed particularly well at clinically relevant liver fat thresholds of 12–17% and 20–22%. This capability positions TAEUS Liver as a promising solution not only for routine clinical use but also for pharmaceutical applications, including patient selection and monitoring in clinical trials.
Reproducibility and Reliability Confirmed
On February 26, 2026, ENDRA shared additional encouraging data from a new study focusing on measurement consistency. The results demonstrated robust intra-user repeatability and inter-user reproducibility—critical attributes for any diagnostic tool intended for long-term disease monitoring.
The study reported an Intraclass Correlation Coefficient (ICC) of 0.89, along with a standard error of measurement of 3.3%, even when operated by independent users. These findings underscore the system’s reliability and potential for widespread adoption in diverse clinical settings.
Addressing a Growing Global Health Challenge
Steatotic liver disease currently affects approximately 30% of adults worldwide, making it a significant and growing public health concern. Despite its prevalence, access to accurate and non-invasive diagnostic tools remains limited, particularly in routine care settings.
ENDRA aims to bridge this gap with TAEUS Liver by offering a solution that combines accuracy with accessibility. Unlike traditional imaging methods that can be costly and less scalable, TAEUS is designed to integrate with handheld ultrasound systems, making it more practical for widespread clinical use.
The company believes this approach could enable earlier detection, improved disease monitoring, and better patient outcomes, while also supporting pharmaceutical companies in clinical research and drug development.
Leadership Perspective on Progress and Future Potential
Alexander Tokman, Chief Executive Officer of ENDRA, expressed confidence in the company’s progress and long-term vision. He emphasized that the past year has been pivotal in strengthening the clinical foundation of TAEUS.
According to Tokman, the technology is now demonstrating performance levels comparable to current standards of care, while maintaining key advantages such as affordability, scalability, and ease of use.
He also noted that as the company explores strategic alternatives, its primary focus remains on translating this clinical progress into tangible value for patients, healthcare providers, and shareholders.
Fourth Quarter 2025 Financial Performance
For the fourth quarter of 2025, ENDRA reported a mixed financial picture, with improvements in certain areas and increased cash usage in others.
Cash used in operations rose slightly to $1.6 million, compared with $1.5 million during the same period in 2024. This increase reflects ongoing investments in technology development and clinical validation efforts.
However, operating expenses saw a significant decline, dropping to $1.6 million from $4.3 million in the fourth quarter of the previous year. This reduction is indicative of the company’s efforts to streamline operations and manage costs more effectively.
As a result, the company’s net loss for the quarter improved to $3.2 million, compared with a net loss of $4.2 million in the fourth quarter of 2024.
Full-Year 2025 Financial Results
ENDRA’s financial performance for the full year 2025 reflects the impact of strategic actions taken in 2024 to optimize operations and focus on core priorities.
Operating expenses for the year decreased substantially to $5.8 million, down from $10.8 million in 2024. The prior year’s expenses included a $2.3 million non-cash inventory valuation charge, which was associated with a strategic shift to better align the TAEUS Liver device with larger market opportunities.
The company reported a net loss of $7.0 million for 2025, a notable improvement from the $11.5 million net loss recorded in 2024. This progress was primarily driven by reduced operating expenses, although it was partially offset by continued investments in technology advancement and clinical programs.
Liquidity and Capital Strategy
As of December 31, 2025, ENDRA reported approximately $762,000 in cash and cash equivalents. In addition, the company held about $2.0 million in its Digital Asset Treasury.
This digital asset component represents an alternative approach to capital management, reflecting the company’s efforts to diversify its financial resources. While relatively uncommon, such strategies may offer additional flexibility in managing liquidity and supporting ongoing operations.
Outlook and Future Direction
Looking ahead, ENDRA appears focused on two parallel priorities: advancing its TAEUS Liver technology toward broader adoption and completing its strategic review process.
The strong clinical data generated over the past year provides a solid foundation for future growth, particularly as the demand for non-invasive diagnostic tools continues to rise. At the same time, the company’s streamlined cost structure and improved financial performance suggest a more disciplined and focused operational approach.
The outcome of the strategic alternatives review could play a significant role in shaping ENDRA’s future trajectory. Whether through partnerships, acquisitions, or other strategic moves, the company aims to unlock greater value from its technology and market position.
ENDRA Life Sciences’ 2025 results highlight a year of meaningful progress, both clinically and financially. With promising data supporting the effectiveness of TAEUS Liver and a clear commitment to operational efficiency, the company is positioning itself for the next phase of growth.
As it evaluates strategic options and continues to refine its technology, ENDRA remains focused on addressing a critical unmet need in liver disease diagnostics while delivering value to its stakeholders.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS® is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. Our press releases and financial and other material information are routinely posted to and accessible on the Investors section
